Pan-immune-inflammatory value in patients with hyperuricemia: a population-based study

Area of Science:

• Biomarkers and Public Health

Background:

• Systemic inflammation is implicated in various chronic diseases.
• The pan-immune-inflammation value (PIV) is an emerging biomarker reflecting systemic inflammation.
• Hyperuricemia is a condition associated with increased cardiovascular risk.

Purpose of the Study:

• To investigate the association between PIV and hyperuricemia prevalence in US adults.
• To examine the relationship between PIV and the risk of hyperuricemia.
• To assess the impact of PIV on all-cause and cardiovascular mortality in hyperuricemic individuals.

Main Methods:

• Utilized data from the National Health and Nutrition Examination Survey (NHANES) 2007-2018.
• Calculated PIV using neutrophil, platelet, monocyte, and lymphocyte counts.
• Defined hyperuricemia based on established uric acid level thresholds for males and females.

Main Results:

• A total of 31,151 participants were analyzed.
• Hyperuricemia prevalence increased with higher PIV levels (P < 0.001).
• Higher PIV quartiles were associated with an increased risk of hyperuricemia (OR = 1.19, P = 0.001), showing a dose-response relationship.
• Elevated PIV correlated with increased all-cause and cardiovascular mortality in hyperuricemic patients (P < 0.001).

Conclusions:

• PIV is a potential epidemiological tool for assessing immune-inflammatory responses.
• PIV may aid in evaluating hyperuricemia risk and its prognostic implications.
• The study highlights PIV's role in understanding hyperuricemia and associated mortality risks.